NeuroOne Medical Technologies (NMTC) 10-K 17 Dec 24 2024 FY Annual report Financial data

Cover

Cover - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Dec. 13, 2024	Mar. 28, 2024
Document Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Transition Report	false
Document Financial Statement Error Correction [Flag]	false
Entity Interactive Data Current	Yes
ICFR Auditor Attestation Flag	false
Amendment Flag	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Documents Incorporated by Reference [Text Block]	Parts of the Proxy Statement for the Registrant’s 2025 Annual Meeting of Stockholders to be filed subsequently are incorporated by reference into Part III of this Annual Report on Form 10-K.
Entity Information [Line Items]
Entity Registrant Name	NeuroOne Medical Technologies Corporation
Entity Central Index Key	0001500198
Entity File Number	001-40439
Entity Tax Identification Number	27-0863354
Entity Incorporation, State or Country Code	DE
Current Fiscal Year End Date	--09-30
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Public Float			$ 30.3
Entity Contact Personnel [Line Items]
Entity Address, Address Line One	7599 Anagram Dr.
Entity Address, City or Town	Eden Prairie
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55344
Entity Phone Fax Numbers [Line Items]
City Area Code	952
Local Phone Number	426-1383
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	NMTC
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		30,841,830

Audit Information

Audit Information	12 Months Ended
	Sep. 30, 2024
Auditor [Table]
Auditor Name	Baker Tilly US, LLP
Auditor Firm ID	23
Auditor Location	Minneapolis, Minnesota

Balance Sheets

Balance Sheets - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Current assets:
Cash and cash equivalents	$ 1,460,042	$ 5,322,493
Accounts receivable	176,636
Inventory	2,635,153	1,726,686
Deferred offering costs	142,633
Prepaid expenses	216,461	263,746
Total current assets	4,630,925	7,312,925
Intangible assets, net	67,262	89,577
Right-of-use asset	254,910	169,059
Property and equipment, net	416,843	525,753
Total assets	5,369,940	8,097,314
Current liabilities:
Accounts payable	1,029,206	685,104
Accrued expenses and other liabilities	1,184,014	1,107,522
Total current liabilities	2,213,220	1,792,626
Warrant liability	2,140,315
Operating lease liability, long term	194,392	55,284
Total liabilities	4,547,927	1,847,910
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding.
Common stock, $0.001 par value; 100,000,000 shares authorized; 30,816,499 and 23,928,945 shares issued and outstanding as of September 30, 2024 and 2023, respectively.	30,816	23,929
Additional paid–in capital	75,795,610	68,911,778
Accumulated deficit	(75,004,413)	(62,686,303)
Total stockholders’ equity	822,013	6,249,404
Total liabilities and stockholders’ equity	$ 5,369,940	$ 8,097,314

Balance Sheets (Parentheticals)

Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2024	Sep. 30, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	30,816,499	23,928,945
Common stock, shares outstanding	30,816,499	23,928,945

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Product revenue	$ 3,453,003	$ 1,952,441
Cost of product revenue	2,373,336	1,495,924
Product gross profit	1,079,667	456,517
Collaborations revenue		1,455,188
Operating expenses:
Selling, general and administrative	7,901,695	6,926,269
Research and development	5,065,181	6,940,686
Total operating expenses	12,966,876	13,866,955
Loss from operations	(11,887,209)	(11,955,250)
Fair value change in warrant liability	(327,092)
Financing costs	(228,988)
Other income, net	125,179	95,759
Loss before income taxes	(12,318,110)	(11,859,491)
Provision for income taxes
Net loss	$ (12,318,110)	$ (11,859,491)
Net loss per share:
Basic (in Dollars per share)	$ (0.46)	$ (0.65)
Diluted (in Dollars per share)	$ (0.46)	$ (0.65)
Number of shares used in per share calculations:
Basic (in Shares)	26,762,392	18,121,108
Diluted (in Shares)	26,762,392	18,121,108

Statements of Changes in Stockh

Statements of Changes in Stockholders’ Equity - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Sep. 30, 2022	$ 16,217	$ 60,414,959	$ (50,826,812)	$ 9,604,364
Balance (in Shares) at Sep. 30, 2022	16,216,540
Issuance of common stock in connection with public offering	$ 6,038	6,031,462		6,037,500
Issuance of common stock in connection with public offering (in Shares)	6,037,500
Issuance of common stock in connection with at-the-market offering program	$ 1,440	2,551,216		2,552,656
Issuance of common stock in connection with at-the-market offering program (in Shares)	1,439,677
Issuance costs in connection with common stock issuances		(1,071,663)		(1,071,663)
Stock-based compensation		1,105,457		1,105,457
Issuance of common stock upon vesting of restricted stock units	$ 313	(313)
Issuance of common stock upon vesting of restricted stock units (in Shares)	314,485
Share repurchases for the payment of employee taxes	$ (79)	(119,340)		(119,419)
Share repurchases for the payment of employee taxes (in Shares)	(79,257)
Net loss			(11,859,491)	(11,859,491)
Balance at Sep. 30, 2023	$ 23,929	68,911,778	(62,686,303)	6,249,404
Balance (in Shares) at Sep. 30, 2023	23,928,945
Issuance of common stock in connection with 2024 Private Placement	$ 2,944	833,833		836,777
Issuance of common stock in connection with 2024 Private Placement (in Shares)	2,944,446
Issuance of common stock in connection with at-the-market offering program	$ 3,749	5,030,157		5,033,906
Issuance of common stock in connection with at-the-market offering program (in Shares)	3,748,913
Issuance costs in connection with common stock issuances		(296,161)		(296,161)
Stock-based compensation		1,344,476		1,344,476
Issuance of common stock upon vesting of restricted stock units	$ 267	(267)
Issuance of common stock upon vesting of restricted stock units (in Shares)	267,305
Share repurchases for the payment of employee taxes	$ (73)	(81,330)		(81,403)
Share repurchases for the payment of employee taxes (in Shares)	(73,110)
Issuance of warrants in connection with debt facility		53,124		53,124
Net loss			(12,318,110)	(12,318,110)
Balance at Sep. 30, 2024	$ 30,816	$ 75,795,610	$ (75,004,413)	$ 822,013
Balance (in Shares) at Sep. 30, 2024	30,816,499

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Operating activities
Net loss	$ (12,318,110)	$ (11,859,491)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization and depreciation	246,791	199,266
Amortization of deferred issuance costs	101,329
Stock-based compensation	1,344,476	1,105,457
Fair value change in warrant liability	327,092
Private placement warrant issuance costs reclassed to financing activities	127,659
Loss on disposal of fixed assets		32,143
Amortization of discounts and premiums on short-term investments		(45,571)
Non-cash lease expense	113,534	109,832
Change in assets and liabilities:
Accounts receivable	(176,636)	33,237
Inventory	(908,467)	(1,022,148)
Prepaid expenses	47,285	32,903
Accounts payable	66,993	(247,189)
Accrued expenses, deferred revenue, operating lease and other liabilities	16,214	(1,225,313)
Net cash used in operating activities	(11,011,840)	(12,886,874)
Investing activities
Purchases of short-term investments		(1,473,419)
Maturities of short-term investments		4,500,000
Proceeds from the disposal of fixed assets		7,500
Purchases of property and equipment	(120,197)	(384,117)
Net cash (used in) provided by investing activities	(120,197)	2,649,964
Financing activities
Proceeds from issuance of common stock in connection with private placement	836,777	6,037,500
Proceeds from issuance of warrants in connection with private placement	1,813,223
Proceeds from issuance of common stock in connection with at-the-market offering program	5,033,906	2,552,656
Issuance costs attributed to common stock and warrants issued in private placement	(1,320)	(836,938)
Issuance costs in connection with at-the-market offering program	(236,597)	(234,725)
Deferred issuance costs in connection with at-the-market offering program	(20,000)
Deferred issuance costs in connection with debt facility	(75,000)
Share repurchases for the payment of employee taxes	(81,403)	(119,419)
Net cash provided by financing activities	7,269,586	7,399,074
Net decrease in cash and cash equivalents	(3,862,451)	(2,837,836)
Cash and cash equivalents at beginning of year	5,322,493	8,160,329
Cash and cash equivalents at end of year	1,460,042	5,322,493
Supplemental non-cash financing and investing transactions:
Unpaid purchases of property and equipment		4,631
Modification of right-of-use asset and associated lease liability	199,385	97,536
Non-cash warrants issued in connection with debt facility	53,124
Unpaid issuance costs in connection with private placement	185,903
Unpaid deferred issuance costs	$ 95,837

Organization and Nature of Oper

Organization and Nature of Operations	12 Months Ended
	Sep. 30, 2024
Organization and Nature of Operations [Abstract]
Organization and Nature of Operations	NOTE 1 - Organization and Nature of Operations NeuroOne Medical Technologies Corporation (the “Company” or “NeuroOne”), a Delaware corporation, is a medical technology company focused on the development and commercialization of thin film electrode for continuous electroencephalogram (“cEEG”) and stereoelectrocencephalography (“sEEG”) recording, monitoring, ablation, drug delivery and brain stimulation solutions to diagnose and treat patients with epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. The Company received 510(k) clearance from the United States (“U.S.”) Food and Drug Administration (“FDA”) for its Evo cortical electrode technology in November 2019 and in October 2022, the Company received 510(k) clearance from the FDA for its Evo® sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain. In December 2023, we received 510(k) clearance for our OneRF Ablation System for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures. The Company is based in Eden Prairie, Minnesota. Global Economic Conditions Generally, worldwide economic conditions remain uncertain, particularly due to the conflicts between Russia and Ukraine and in the Middle East, disruptions in the banking system and financial markets, and increased inflation. The general economic and capital market conditions both in the U.S. and worldwide, have been volatile in the past and at times have adversely affected the Company’s access to capital and increased the cost of capital. The capital and credit markets may not be available to support future capital raising activity on favorable terms or at all. If economic conditions continue to decline, the Company’s future cost of equity or debt capital and access to the capital markets could be adversely affected. The Company’s operating results could be materially impacted by changes in the overall macroeconomic environment and other economic factors. Changes in economic conditions, supply chain constraints, logistics challenges, labor shortages, the conflicts in Ukraine and the Middle East, disruptions in the banking system and financial markets, and steps taken by governments and central banks, have led to higher inflation, which has led to an increase in costs and has caused changes in fiscal and monetary policy, including increased interest rates.

Going Concern

Going Concern	12 Months Ended
	Sep. 30, 2024
Going Concern [Abstract]
Going Concern	NOTE 2 - Going Concern The accompanying financial statements have been prepared on the basis that the Company will continue as a going concern. The Company has incurred losses since inception, negative cash flows from operations, and an accumulated deficit of $75.0 million as of September 30, 2024. To date, the Company’s revenues have not been sufficient to cover its full operating costs, and as such, it has been dependent on funding operations through the issuance of debt and sale of equity securities. The Company has adequate liquidity, including the net proceeds from the 2024 Private Placement (See Note 9 – Stockholders’ Equity) and the 2024 Debt Facility (See Note 10 - Debt Financing), to fund its operations through April 2025. The raising of additional funds is not solely within the control of the Company. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this condition. If the Company is unable to raise additional funds, or the Company’s anticipated operating results are not achieved, management believes planned expenditures may need to be reduced in order to extend the time period that existing resources can fund the Company’s operations. The Company intends to fund ongoing activities by utilizing its current cash and cash equivalents on hand, from product and collaborations revenue and by raising additional capital through equity or debt financings. If management is unable to obtain the necessary capital, it may have a material adverse effect on the operations of the Company and the development of its technology, or the Company may have to cease operations altogether.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Sep. 30, 2024
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 3 - Summary of Significant Accounting Policies Basis of Presentation The accompanying financial statements have been prepared in accordance with accounting standards generally accepted in the United States of America (“U.S. GAAP”). Reclassifications Certain amounts presented in the prior year period have been reclassified to conform to current period financial statement presentation. The financing proceeds and issuance costs attributed to the at-the-market offering program and private placement reflected in the statements of cash flows during the comparable prior year period were reclassified into two separate line item categories. Management’s Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Segment Information Operating segments are components of an enterprise for which separate financial information is available and are evaluated regularly by the Company’s chief operating decision maker in deciding how to allocate resources and assessing performance. The Company’s chief operating decision maker is its Chief Executive Officer. The Company’s Chief Executive Officer views the Company’s operations and manages its business in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions. Accordingly, the Company has a single reporting segment. Cash and Cash Equivalents The Company considers all highly liquid investments with an original contractual maturity on date of purchase of less than or equal to three months to be classified and presented as cash equivalents on the balance sheets. Cash equivalents are stated at cost, which approximates fair value. The Company’s cash and cash equivalents may include demand deposit accounts with large financial institutions, institutional money market funds, U.S. Treasury securities, and corporate notes and bonds. The Company monitors the creditworthiness of the financial institutions, institutional money market funds, and corporations in which the Company invests its surplus funds. The Company has experienced no credit losses from its cash and cash equivalent investments. Short-Term Investments The Company has periodically invested its excess cash in U.S. Treasury securities and highly rated corporate securities. The Company has held these investments to maturity. Securities with original maturity dates of more than three months were reported as held-to-maturity investments and were recorded at amortized cost, which approximated fair value due to the negligible risk of changes in value due to interest rates. There were no short-term investments outstanding as of September 30, 2024 and 2023. Revenue Recognition The Company entered into a development and distribution agreement which has current and future revenue recognition implications. In addition, the Company has product revenue in connection with its OneRF product offerings (“OneRF Products”) which is not covered by a distribution agreement. See “Note 7 – In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in Accounting Standards Codification (“ASC”) Topic 606 (“ASC 606”). Performance obligations may include license rights, development services, and services associated with regulatory submission and approval processes. Significant management judgment is required to determine the level of effort required under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations are either completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Product Revenue Revenues from product sales are recognized when control of the promised goods or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. When the Company has consigned inventory at a customer, revenue is recognized at the point in time when the customer issues a purchase order to the Company and when control of the promised goods or services is transferred to the Company’s customers. At the inception of each customer contract, performance obligations are identified and the total transaction price is allocated to the performance obligations. Cost of Product Revenue Cost of product revenue consists of the manufacturing and materials costs incurred by the Company’s third-party contract manufacturer in connection with the Company’s strip and grid cortical electrodes (the “Strip/Grid Products”), depth electrodes (“sEEG Products), OneRF Products and outside supplier materials costs in connection with the electrode cable assembly products (“Electrode Cable Assembly Products”). In addition, cost of product revenue includes royalty fees incurred in connection with the Company’s license agreements. Collaborations Revenue As part of the accounting for collaboration arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. The Company allocates the total transaction price to each performance obligation based on the estimated relative standalone selling prices of the promised goods or service underlying each performance obligation. Licenses of intellectual property Milestone payments Royalties Warrant Liability The Company issued warrants in connection with its 2024 Private Placement (See Note 9– Stockholders’ Equity). The Company accounts for these warrants as a liability at fair value when warrant pricing protection provisions are not available to other common stockholders. Additionally, issuance costs associated with the warrant liability are expensed as incurred and reflected as a financing cost in the accompanying statements of operations. The Company adjusts the liability for changes in fair value until the earlier of the exercise or expiration of the warrants for any period when pricing protections remain in place. Any future change in fair value of the warrant liability, when outstanding, is recognized in the statements of operations under the fair value change in warrant liability line item. Fair Value of Financial Instruments The Company’s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (“FASB”) fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows: ● Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date. ● Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. ● Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. As of September 30, 2024 and 2023, the fair values of cash, cash equivalents, accounts receivable, inventory, prepaids and deferred offering costs, accounts payable and accrued expenses and other liabilities approximated their carrying values because of the short-term nature of these assets or liabilities. The fair value of the warrant liability was based on Level 3 inputs as well the Company’s underlying stock price and associated volatility, expected term of the warrants and market interest rates. There were no transfers between fair value hierarchy levels during the years ended September 30, 2024 and 2023. The fair value of financial instruments measured on a recurring basis is as follows: As of September 30, 2024 Description Total Level 1 Level 2 Level 3 Liabilities: Warrant liability $ 2,140,315 $ — $ — $ 2,140,315 Total liabilities at fair value $ 2,140,315 $ — $ — $ 2,140,315 There was not a warrant liability as of September 30, 2023. The following table provides a roll-forward of the warrant liability measured at fair value on a recurring basis using unobservable level 3 inputs for the year ended September 30, 2024. 2024 Warrant liability Balance as of beginning of year $ — Value assigned to warrants in connection with 2024 Private Placement 1,813,223 Change in fair value of warrant liability 327,092 Balance as of end of year $ 2,140,315 Intellectual Property The Company has entered into two licensing agreements with major research institutions, which allow for access to certain patented technology and know-how. Payments under those agreements are capitalized and amortized to selling, general and administrative expense over the expected useful life of the acquired technology. Property and Equipment Property and equipment is recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful lives of the assets using the straight-line method. The estimated useful life for equipment and furniture ranges from three to seven years. Tangible assets acquired for research and development activities and that have alternative use are capitalized over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and, when appropriate, changes are made prospectively. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged directly to expense as incurred. Impairment of Long-Lived Assets The Company evaluates its long-lived assets, which consist of licensed intellectual property, property and equipment and right-of-use assets for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. Accounts Receivable and Allowances for Credit Losses The Company records a provision for credit losses, when appropriate, based on historical experience, current conditions and reasonable supportable forecasts. In estimating the allowance for credit losses, the Company considers, among other factors, the estimate of credit losses over the remaining expected life of the asset, primarily using historical experience and current economic conditions that could affect the collectability of the balances in the future. Account balances are charged off against the allowance when the Company believes that it is probable that the receivable will not be recovered. Actual write-offs may be in excess of the Company’s estimated allowance. The Company has not incurred any bad debt expense to date and no allowance for credit losses has been recorded during the periods presented. Inventory Inventory is stated at the lower of cost (using the first-in, first-out “FIFO” method) or net realizable value. The Company calculates inventory valuation adjustments for excess and obsolete inventory, when appropriate, based on current inventory levels, movement, expected useful lives, and estimated future demand of the products and spare parts. The Company’s inventory is currently comprised of Strip/Grid Products, sEEG Products, OneRF Products and Electrode Cable Assembly Products component, work-in-process and finished good product. The Strip/Grid Products, sEEG Products and OneRF Products are produced by a third-party contract manufacturer and the Electrode Cable Assembly Products are obtained from outside suppliers. No inventory valuation allowance was required during the periods presented. Research and Development Costs Research and development costs are charged to expense as incurred. Research and development expenses comprise of costs incurred in performing research and development activities, including compensation and benefits for research and development employees (including stock-based compensation), overhead expenses, cost of laboratory supplies, clinical trial and related clinical manufacturing expenses, costs related to regulatory operations, fees paid to consultants and other outside expenses. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with ASC 730, Research and Development Advertising Expense Advertising expense is charged to selling, general and administrative expenses during the period that it is incurred. Total advertising expense amounted to $108,993 and $173,430 for the years ended September 30, 2024 and 2023, respectively. Selling, General and Administrative Selling, general and administrative expenses consist primarily of personnel-related costs including stock-based compensation for personnel in functions not directly associated with research and development activities. Other significant costs include legal and litigation costs relating to corporate matters, intellectual property costs, professional fees for consultants assisting with financial and administrative matters, and sales and marketing in connection with the commercial sales of the Company’s products. Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the provisions of ASC 718, Compensation — Stock Compensation Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Net Loss Per Share Basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company’s warrants, stock options, and restricted stock units while outstanding are considered common stock equivalents for this purpose. Diluted earnings or loss per share of common stock is computed utilizing the treasury method for the warrants, stock options and restricted stock units. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the years ended September 30, 2024 and 2023. The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the years ended September 30: 2024 2023 Warrants 7,045,875 6,202,426 Stock options 2,814,096 1,708,427 Restricted stock units 1,129,762 393,370 Recent Accounting Pronouncements In November 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-07 - Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures In June 2016, the FASB issued Accounting Standards Update 2016-13, Financial Instruments – Credit Losses

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Sep. 30, 2024
Commitments and Contingencies [Abstract]
Commitments and Contingencies	NOTE 4 - Commitments and Contingencies WARF License Agreement The Company has entered into an exclusive start-up company license agreement with the Wisconsin Alumni Research Foundation (“WARF”) for WARF’s neural probe array and thin film micro electrode technology (the “WARF Agreement”). The Company entered into an Amended and Restated Exclusive Start-up Company License Agreement (the “WARF License”) with WARF on January 21, 2020, which amended and restated in full the prior license agreement between WARF and NeuroOne, LLC, a predecessor of the Company, dated October 1, 2014, as amended on February 22, 2017, March 30, 2019 and September 18, 2019. The WARF License grants to the Company an exclusive license to make, use and sell, in the United States only, products that employ certain licensed patents for a neural probe array or thin-film micro electrode array and method. The Company agreed to pay WARF a royalty equal to a single-digit percentage of our product sales pursuant to the WARF License, with a minimum annual royalty payment of $50,000 for 2020, $100,000 for 2021 and $150,000 for 2022 and each calendar year thereafter that the WARF License is in effect. If the Company or any of its sublicensees contest the validity of any licensed patent, the royalty rate will be doubled during the pendency of such contest and, if the contested patent is found to be valid and would be infringed by the Company if not for the WARF License, the royalty rate will be tripled for the remaining term of the WARF License. WARF may terminate the WARF License on 30 days’ written notice if we default on the payments of amounts due to WARF or fail to timely submit development reports, actively pursue our development plan or breach any other covenant in the WARF License and fail to remedy such default in 90 days or in the event of certain bankruptcy events involving us. WARF may also terminate the WARF License (i) on 90 days’ notice if we had failed to have commercial sales of one or more FDA-approved products under the WARF License by June 30, 2021 or (ii) if, after royalties earned on sales begin to be paid, such earned royalties cease for more than four calendar quarters. The first commercial sale occurred on December 7, 2020, prior to the June 30, 2021 deadline. The WARF License otherwise expires by its terms on the date that no valid claims on the patents licensed thereunder remain. The Company expects the latest expiration of a licensed patent to occur in 2030. During each of the years ended September 30, 2024 and 2023, $150,000 in royalty fees were incurred related to the WARF License and were reflected as a component of cost of product revenue. Mayo Agreement The Company has an exclusive license and development agreement with the Mayo Foundation for Medical Education and Research (“Mayo”) related to certain intellectual property and development services for thin film micro electrode technology (“Mayo Agreement”). If the Company is successful in obtaining regulatory approval, the Company is to pay royalties to Mayo based on a percentage of net sales of products of the licensed technology through the term of the Mayo Agreement, set to expire May 25, 2037. During the years ended September 30, 2024 and 2023, $6,861 and $7,486 in royalty fees were incurred, respectively, and were reflected as a component of cost of product revenue. Facility Leases Headquarters Lease On May 20, 2024, the Company amended its non-cancellable headquarters lease (the “Lease”) with certain landlords (together, the “Landlord”) pursuant to which the Company leases office space located at 7599 Anagram Drive, Eden Prairie, Minnesota (the “Premises”). The Company took possession of the Premises on November 1, 2019, with the term of the Lease ending June 30, 2028, as amended, unless terminated earlier (the “Lease Term”). The base rent for the Premises ranges from $6,410 per month to $7,107 per month by the end of the Lease Term as amended. In addition, as long as the Company is not in default under the Lease, the Company will be entitled to an abatement of its base rent for the first two months of the amended Lease Term beginning in April 2025 and for the last month of the amended Lease Term (June 2028). In addition, the Company pays its pro rata share of the Landlord’s annual operating expenses associated with the Premises. Los Gatos Lease On July 1, 2021, the Company entered into a non-cancellable facility lease (the “Los Gatos Lease”), pursuant to which the Company agreed to rent office space for its research and development operations located at 718 University Avenue, Suite #111, Los Gatos, California. The facility space under the Los Gatos Lease is approximately 1,162 square feet. The Company took possession of the office space on July 2, 2021. The initial monthly rent under the Los Gatos Lease was $4,241. On November 4, 2022, the Los Gatos Lease was extended for an additional two years to December 31, 2024. The rent under the extended Los Gatos Lease ranges from $4,453 to $4,632 per month beginning on January 1, 2023. During the years ended September 30, 2024 and 2023, rent expense associated with the facility leases amounted to $173,090 and $171,633, respectively. Supplemental cash flow information related to the operating lease For the Years Ended 2024 2023 Cash paid for amounts included in the measurement of lease liability: Operating cash flows from operating leases $ 138,917 $ 134,632 Modification of right-of-use asset and associated lease liability: Operating leases $ 199,385 $ 97,536 Supplemental balance sheet information related to the operating lease was as follows: As of 2024 2023 Right-of-use assets $ 254,910 $ 169,059 Lease liability $ 260,160 $ 184,400 Weighted average remaining lease term (years) 3.6 1.4 Weighted average discount rate 7.4 % 7.8 % Maturity of the lease liability was as follows: Calendar Year As of 2024 $ 35,122 2025 66,097 2026 78,945 2027 81,708 2028 34,815 Total lease payments 296,687 Less imputed interest (36,527 ) Total 260,160 Short term portion in accrued expenses and other liabilities (65,768 ) Long term portion $ 194,392

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	12 Months Ended
	Sep. 30, 2024
Supplemental Balance Sheet Information [Abstract]
Supplemental Balance Sheet Information	NOTE 5 - Supplemental Balance Sheet Information Inventory Inventory consisted of the following: As of 2024 2023 Component inventory $ 877,065 $ 1,202,778 Work-in-process 192,360 343,597 Finished goods 1,565,728 180,311 Total $ 2,635,153 $ 1,726,686 The Company had finished goods on consignment in the amount of $102,318 as of September 30, 2024. There was no consigned inventory as of September 30, 2023. Intangibles Intangible assets roll forward is as follows: Useful Life Net intangibles, September 30, 2022 12-13 years $ 111,892 Less: amortization (22,315 ) Net intangibles, September 30, 2023 89,577 Less: amortization (22,315 ) Net intangibles, September 30, 2024 $ 67,262 The Company anticipates amortization expense of approximately $22,000 per year for fiscal year 2025 through 2027 based upon the two current license agreements. Property and Equipment Property and equipment, net held for use by category are presented in the following table: As of 2024 2023 Equipment and furniture $ 976,303 $ 860,737 Total property and equipment 976,303 860,737 Less accumulated depreciation (559,460 ) (334,984 ) Property and equipment, net $ 416,843 $ 525,753 Depreciation expense was $224,476 and $176,951 for the years ended September 30, 2024 and 2023, respectively. Equipment with a net book value of $39,643 was disposed by the Company resulting in net proceeds of $7,500 during the year ended September 30, 2023.

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	12 Months Ended
	Sep. 30, 2024
Accrued Expenses and Other Liabilities [Abstract]
Accrued Expenses and Other Liabilities	NOTE 6 - Accrued Expenses and Other Liabilities Accrued expenses and other liabilities consisted of the following As of 2024 2023 Accrued payroll $ 950,260 $ 874,382 Operating lease liability, short term 65,768 129,116 Royalty fees 108,036 104,024 Other 59,950 — Total $ 1,184,014 $ 1,107,522

Zimmer Development Agreement an

Zimmer Development Agreement and Other Product Revenue	12 Months Ended
	Sep. 30, 2024
Zimmer Development Agreement and Other Product Revenue [Abstract]
Zimmer Development Agreement and Other Product Revenue	NOTE 7 - Zimmer Distribution Agreement and Other Product Revenue On July 20, 2020, the Company entered into an exclusive development and distribution agreement (the “Zimmer Distribution Agreement”) with Zimmer, Inc. (“Zimmer”), pursuant to which the Company granted Zimmer exclusive global rights to distribute the Strip/Grid Products and the Electrode Cable Assembly Products. Additionally, the Company granted Zimmer the exclusive right and license to distribute certain sEEG Products developed by the Company and together with the Strip/Grid Products and Electrode Cable Assembly Products, the “Products”. The parties have agreed to collaborate with respect to development activities under the Zimmer Distribution Agreement through a joint development committee composed of an equal number of representatives of Zimmer and the Company. Under the terms of the Zimmer Distribution Agreement, the Company is responsible for all costs and expenses related to developing the Products, and Zimmer is responsible for all costs and expenses related to the commercialization of the Products. In addition to the Zimmer Distribution Agreement, Zimmer and the Company have entered into a Manufacturing and Supply Agreement and a Supplier Quality Agreement with respect to the manufacturing and supply of the Products. Except as otherwise provided in the Zimmer Distribution Agreement, the Company is responsible for performing all development activities, including non-clinical and clinical studies directed at obtaining regulatory approval of each Product. Zimmer has agreed to use commercially reasonable efforts to promote, market and sell each Product following the “Product Availability Date” (as defined in the Zimmer Distribution Agreement) for such Product. Pursuant to the Zimmer Distribution Agreement, Zimmer made an upfront initial exclusivity fee payment of $2.0 million (the “Initial Exclusivity Fee”) to the Company in fiscal year 2020. On August 2, 2022, the Company entered into a Third Amendment to Exclusive Development and Distribution Agreement (the “Zimmer Amendment”) with Zimmer. Pursuant to the terms and conditions of the Zimmer Amendment, Zimmer made a $3.5 million payment to the Company. In consideration of the mutual covenants and agreements contained in the Zimmer Distribution Agreement, the fee and milestone payment provisions in the Zimmer Distribution Agreement were replaced with the following below: ● $1.5 million for the sEEG Exclusivity Maintenance Fee; and ● $2.0 million for satisfaction of each of the milestone events related to the design of sEEG Products set forth in the Zimmer Distribution Agreement even though the satisfaction was after the deadlines originally identified. In addition, in connection with the Zimmer Amendment, the Company issued Zimmer a warrant to purchase common stock (the “2022 Zimmer Warrant”). The 2022 Zimmer Warrant is exercisable for up to an aggregate of 350,000 shares of the Company’s common stock. The 2022 Zimmer Warrant has an exercise price of $3.00 per share, is exercisable commencing six months from the issuance date, and will expire on August 2, 2027. The fair value of the 2022 Zimmer Warrant of $0.1 million was based on the Black-Scholes pricing model. Input assumptions used were as follows: a risk-free interest rate of 2.9%; expected volatility of 53.5%; expected life of 5 years; expected dividend yield of 0%; and the underlying fair market of the common stock. The 2022 Zimmer Warrant was classified in stockholders’ equity as the number of shares were fixed and determinable, no cash settlement was required and no other provisions precluded equity treatment. The Zimmer Distribution Agreement will expire on the tenth anniversary of the date of the first commercial sale of the last Products to achieve a first commercial sale, unless terminated earlier pursuant to its terms. Either party may terminate the Zimmer Distribution Agreement (x) with written notice for the other party’s material breach following a cure period or (y) if the other party becomes subject to certain insolvency proceedings. In addition, Zimmer may terminate the Zimmer Distribution Agreement for any reason with 90 days’ written notice, and the Company may terminate the Zimmer Distribution Agreement if Zimmer acquires or directly or indirectly owns a controlling interest in certain competitors of the Company. The license rights granted to Zimmer under the Strip/Grid Distribution License and sEEG Distribution License as defined in the Zimmer Distribution Agreement shall be exclusive from the effective date of the Zimmer Amendment until the end of the term of the Zimmer Amendment. The Zimmer Distribution Agreement and Zimmer Amendment were accounted for under the provisions of ASC 606. In accordance with the provisions under ASC 606, the Company identified five performance obligations under the Zimmer Distribution Agreement and Zimmer Amendment: (1) the Company’s obligation to grant Zimmer access to its intellectual property; (2) completion of sEEG Product development; (3) completion of Strip/Grid Product development; (4) the provision of sEEG exclusivity maintenance; and (5) completion of sEEG design modifications as requested by Zimmer. All performance obligations under the Zimmer Distribution Agreement and Zimmer Amendment, outside of the sEEG exclusivity maintenance obligation, were met by September 30, 2022. The remaining performance obligation in deferred revenue as of September 30, 2022 attributed to sEEG exclusivity maintenance was completed in first quarter of fiscal year 2023. The aggregate transaction price associated with the Zimmer Distribution Agreement and Zimmer Amendment was $5.4 million comprising the Initial Exclusivity Fee of $2.0 million and the $3.5 million payment under the Zimmer Amendment, less the fair value 2022 Zimmer Warrant of $0.1 million. The transaction price was allocated between performance obligations based on their relative standalone selling prices. The Company used a market based valuation approach and an expected cost plus margin approach with regard to estimating the standalone selling price for the performance obligations. The Company recognized collaborations revenue in the amount of $1,455,188 during the year ended September 30, 2023 in connection with the Zimmer Distribution Agreement and Zimmer Amendment. Given the achievement of the milestones under the Zimmer Distribution Agreement and Zimmer Amendment by December 31, 2022, no A reconciliation of the closing balance of deferred revenue related to the Zimmer Distribution Agreement and the Zimmer Amendment is as follows as of September 30, 2024 and 2023: Deferred Revenue Balance as of September 30, 2022 $ 1,455,188 Revenue recognized (1,455,188 ) Balance as of September 30, 2023 — Revenue recognized — Balance as of September 30, 2024 $ — Product Revenue Product revenue related to the Company’s Strip/Grid Products, sEEG Products, OneRF Products and Electrode Cable Assembly Products. Product revenue recognized during the years ended September 30, 2024 and 2023 was $3,453,003 and $1,952,441, respectively, inclusive of OneRF Product revenue that amounted to $340,185 during the year ended September 30, 2024. There was no OneRF Product revenue recognized during the prior year period presented. The OneRF Products were not covered by the Zimmer Distribution Agreement during the year ended September 30, 2024.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Sep. 30, 2024
Stock-Based Compensation [Abstract]
Stock-Based Compensation	NOTE 8 - Stock-Based Compensation During the years ended September 30, 2024 and 2023, stock-based expense related to the stock options and restricted stock units was included in selling, general and administrative and research and development costs as follows in the accompanying statements of operations: 2024 2023 Selling, general and administrative $ 1,064,819 $ 905,108 Research and development 279,657 200,349 Total stock-based compensation expense $ 1,344,476 $ 1,105,457 The Company’s 2017 Equity Incentive Plan (“2017 Plan”) provides for the issuance of restricted shares and stock options to employees, directors, and consultants of the Company. Effective October 1, 2021, no Inducement Plan In addition to the Company’s 2017 Equity Incentive Plan (the “2017 Plan”), the Company adopted the NeuroOne Medical Technologies Corporation 2021 Inducement Plan (the “Inducement Plan”) on October 4, 2021, pursuant to which the Company reserved 420,350 shares of its common stock to be used exclusively for grants of awards to individuals who were not previously employees or directors of the Company, as an inducement material to the individual’s entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The Inducement Plan was approved by the Company’s Board of Directors without stockholder approval in accordance with such rule. On November 9, 2023, the Company’s Board of Directors adopted the First Amendment to the Company’s Inducement Plan, increasing the aggregate number of shares of common stock that may be issued pursuant to equity incentive awards under the Inducement Plan by 150,000 shares for a total of 570,350 shares of common stock that may be issued. Evergreen provision Under the 2017 Plan, the shares reserved automatically increase on January 1st of each year, for a period of not more than ten years from the date the 2017 Plan is approved by the stockholders of the Company, commencing on January 1, 2019 and ending on (and including) January 1, 2027, to an amount equal to 13% of the fully-diluted shares outstanding as of December 31st of the preceding calendar year. Notwithstanding the foregoing, the Board of Directors may act prior to January 1st of a given year to provide that there will be no January 1st increase in the share reserve for such year or that the increase in the share reserve for such year will be a lesser number of shares of common stock than would otherwise occur pursuant to the preceding sentence. “Fully Diluted Shares” as of a date means an amount equal to the number of shares of common stock (i) outstanding and (ii) issuable upon exercise, conversion or settlement of outstanding awards under the 2017 Plan and any other outstanding options, warrants or other securities of the Company that are (directly or indirectly) convertible or exchangeable into or exercisable for shares of common stock, in each case as of the close of business of the Company on December 31 of the preceding calendar year. On January 1, 2024 and 2023, 1,051,556 and 129,479 shares were added to the 2017 Plan, respectively, as a result of the evergreen provision. Stock Options During the years ended September 30, 2024 and 2023, 1,225,669 and 459,512 stock options were granted to employees, directors and consultants, respectively, with a weighted average grant date fair value of $1.08 and $0.88 per share, respectively. The options granted have vesting periods ranging from being immediate to four years. All options expire ten years from the date of grant. The total expense for the years ended September 30, 2024 and 2023 related to the stock options was $808,057 and $632,315, respectively. The following table summarizes the Company’s stock option plan activity for the years ended September 30, 2024 and 2023 as follows: Number of Weighted Weighted- Aggregate Outstanding at September 30, 2022 1,239,915 $ 5.40 8.0 $ 89,295 Granted 469,512 $ 1.55 — — Exercised — $ — — — Forfeited/Cancelled (1,000 ) $ 3.78 — — Outstanding at September 30, 2023 1,708,427 $ 4.34 7.7 $ 20,064 Granted 1,225,669 $ 1.26 — — Exercised — $ — — — Forfeited/Cancelled (120,000 ) $ 1.33 — — Outstanding at September 30, 2024 2,814,096 $ 3.13 7.7 $ 22,685 Vested and expected to vest at September 30, 2024 2,814,096 $ 3.13 7.7 $ 22,685 Vested and exercisable at September 30, 2024 1,409,840 $ 4.79 6.4 $ 22,643 (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of our common stock as of September 30, 2024 and 2023 of $0.99 and $0.89 per share, respectively. As of September 30, 2024 and 2023, 2,780,581 and 1,682,912 outstanding options, respectively, had no intrinsic value. The weighted-average assumptions used in the Black-Scholes option-pricing model are as follows for the stock options granted during the years ended September 30: 2024 2023 Expected stock price volatility 111.9 % 57.4 % Expected life of options (years) 6.1 5.8 Expected dividend yield 0 % 0 % Risk free interest rate 4.6 % 3.7 % During the years ended September 30, 2024 and 2023, 289,072 and 337,753 stock options vested, respectively. During the years ended September 30, 2024 and 2023, 120,000 and 1,000 stock options were forfeited, respectively. No Restricted Stock Units A summary of restricted stock unit (“RSU”) activity is as follows for the years ended September 30, 2024 and 2023: Number of Shares Non-vested at September 30, 2022 414,430 Granted 310,728 Vested (331,788 ) Non-vested at September 30, 2023 393,370 Granted 1,006,725 Vested (270,333 ) Non-vested at September 30, 2024 1,129,762 During the years ended September 30, 2024 and 2023, 1,006,725 and 310,728 RSUs were granted to members of the Company’s board of directors and employees with a grant date fair value of $1.03 and $1.60 per unit, respectively. The RSUs granted in fiscal year 2024 vest over a four-year period in equal annual installments on the anniversary date of the grant, subject to the recipient’s continued service on such dates. The RSUs granted in fiscal 2023 vest over a one to three year period with some of the RSUs vesting ratably on a monthly basis and others vesting at 50 percent on the first anniversary of the grant date with the remaining RSUs vesting in equal quarterly installments on the last day of each quarter over 24 months, subject to the recipient’s continued service on such dates. During the years ended September 30, 2024 and 2023, 270,333 and 331,788 RSUs vested, respectively. The total expense for the years ended September 30, 2024 and 2023 related to the RSU’s was $536,419 and $473,142, respectively. No RSUs were forfeited during the years ended September 30, 2024 and 2023. General As of September 30, 2024, 297,461 shares were available for future issuance on a combined basis under the 2017 Plan and the Inducement Plan. Unrecognized stock-based compensation was $2,373,628 as of September 30, 2024. The unrecognized share-based expense is expected to be recognized over a weighted average period of 2.3 years.

Stockholders_ Equity

Stockholders’ Equity	12 Months Ended
	Sep. 30, 2024
Stockholders’ Equity [Abstract]
Stockholders’ Equity	NOTE 9 - Stockholders’ Equity August 2024 Private Placement On August 1, 2024, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company, in a private placement (the “2024 Private Placement”), agreed to issue and sell an aggregate of (i) 2,944,446 shares of the Company’s common stock, par value $0.001 per share and (ii) warrants to purchase an aggregate of 2,208,333 shares of common stock (the “PIPE Warrants”) at a purchase price of $0.90 per unit, consisting of one share and a PIPE Warrant to purchase 0.75 shares of common stock, resulting in total gross proceeds of approximately $2.65 million before deducting expenses. Issuance costs attributed to the 2024 Private Placement amounted to approximately $0.2 million. The 2024 Private Placement closed on August 2, 2024. The PIPE Warrants are exercisable beginning on the date of issuance, have an exercise price of $1.19 per share, subject to adjustment, and will expire on the third anniversary of the date of issuance. One of the Purchasers in the 2024 Private Placement included Paul Buckman, a director on the Company’s Board of Directors. The PIPE Warrants were accounted for and classified as liabilities on the accompanying balance sheets given certain price reset provisions not used for a fair valuation under a fixed for fixed settlement scenario as required for equity balance sheet classification. A Monte Carlo simulation model was used to estimate the aggregate fair value of the PIPE Warrants. Input assumptions used were as follows on August 2, 2024 and September 30, 2024: risk-free interest rate 3.63% and 3.53%, respectively; expected volatility of 116.1% and 115.7%; respectively; expected life of 3 years and 2.84 years, respectively; and expected dividend yield zero percent for both dates. The underlying stock price used was the market price as quoted on Nasdaq as of August 2, 2024 and September 30, 2024. The aggregate fair value of the PIPE Warrants of $1,813,223 upon issuance was recorded as a long term liability on the accompanying balance sheets. The Company recorded the fair value change of the PIPE Warrants in the amount of $327,092 to the fair value change in warrant liability line item on the accompanying statements of operations for the year ended September 30, 2024. At-The-Market Offering On December 21, 2022, the Company entered into a Capital on Demand TM During the years ended September 30, 2024 and 2023, 3,748,913 and 1,439,677 shares of common stock were issued, respectively, under the ATM for an aggregate offering price of $5,033,906 and $ 2,552,656 234,725 The total aggregate offering price and common stock issued since inception of the ATM though September 30, 2024 was $7,586,562 and 5,188,590 shares, respectively. Cumulative issuance costs incurred under the ATM through September 30, 2024 was $512,628 of which $41,305 was included as a deferred cost on the balance sheet as of September 30, 2024. July 2023 Public Offering On July 24, 2023, the Company entered into an underwriting agreement with The Benchmark Company, LLC, as underwriter (“Benchmark”), relating to the issuance and sale of 5,250,000 shares of the Company’s common stock, par value $0.001 per share, at a price to the public of $1.00 per share (the “July 2023 Public Offering”). In addition, under the terms of the July 2023 Public Offering, the Company granted Benchmark an option, exercisable for 30 days, to purchase up to an additional 787,500 shares of common stock on the same terms (“the Overallotment Option”). The July 2023 Public Offering closed on July 27, 2023, and the Company completed the sale and issuance of an aggregate of 6,037,500 shares of its common stock, including the exercise in full of the Overallotment Option. The net proceeds to the Company from the July 2023 Public Offering were approximately $5.2 million after deducting underwriting discounts and other offering expenses payable by the Company. The Company used the net proceeds from this offering to: (i) support the commercial launch of the EVO sEEG electrode with Zimmer Biomet, (ii) support the FDA submission for the OneRF ablation system and (iii) complete the design of a novel drug delivery electrode, among other general corporate purposes. Warrant Activity and Summary The following table summarizes warrant activity during the years ended September 30, 2024 and 2023: Warrants Exercise Weighted Weighted Outstanding and exercisable at September 30, 2022 7,103,344 $ 3.00-9.00 $ 5.98 2.68 Issued — $ — $ — — Exercised — $ — $ — — Expired (900,918 ) $ 5.61-9.00 $ 6.38 — Outstanding and exercisable at September 30, 2023 6,202,426 $ 3.00-9.00 $ 5.92 2.00 Issued 2,308,338 $ 0.66-1.19 $ 1.17 3.09 Exercised — $ — $ — — Expired (1,464,889 ) $ 6.00-9.00 $ 8.59 — Outstanding at September 30, 2024 7,045,875 $ 0.66-5.61 $ 3.81 1.98 Outstanding and exercisable at September 30, 2024 7,045,875 $ 0.66-5.61 $ 3.81 1.98 The following table summarizes information about warrants outstanding at September 30, 2024: Exercise Price Number Outstanding Weighted Average Number Exercisable at $ 0.66 100,000 4.84 100,000 $ 1.19 2,208,338 2.84 2,208,338 $ 3.00 350,000 2.84 350,000 $ 5.25 4,166,682 1.29 4,166,682 $ 5.61 220,855 3.75 220,855 Total 7,045,875 7,045,875

Debt Financing

Debt Financing	12 Months Ended
	Sep. 30, 2024
Debt Financing [Abstract]
Debt Financing	NOTE 10 - Debt Financing Debt Facility Financing On August 2, 2024, the Company entered into a loan and security agreement (the “Debt Facility Agreement”) with Growth Opportunity Funding, LLC, as the lender (the “Lender”), which provides for a delayed draw term loan facility in an aggregate principal amount not to exceed $3.0 million (the “Debt Facility”). The Company was permitted to borrow loans under the Debt Facility from time to time (collectively, the “Loans”), for general corporate purposes and subject to certain specified conditions, until the earliest of: (i) November 30, 2024, (ii) the occurrence of any Monetization Event (as defined below) or Change of Control (as defined in the Debt Facility Agreement), or (iii) at the Lender’s option, upon the occurrence and during the continuance of an event of default under the Debt Facility Agreement. On November 7, 2024, the Company terminated the Debt Facility Agreement (See Note 14 – Subsequent Events). The Loans would have matured on February 2, 2026, if issued. Interest on any outstanding principal amount would have been at a rate of 10% per annum, payable monthly in arrears and at the maturity date. As of September 30, 2024, no amounts were drawn under the Debt Facility Agreement by the Company. At closing of the Debt Facility, the Company issued to the Lender a warrant exercisable for five years for 100,000 shares of common stock at an exercise price of $0.66 per share, subject to adjustment (the “Closing Date Debt Facility Warrant”). The Closing Date Debt Facility Warrant was accounted for and classified as equity on the accompanying balance sheets. At the time of any borrowing of Loans, the Company would have issued to the Lender additional warrants exercisable for five years for 50,000 shares of common stock (for each $500,000 of Loans borrowed) at the same per share exercise price as the Closing Date Debt Facility Warrant ( the “Additional Debt Facility Warrants”, and together with the Closing Date Debt Facility Warrant, the “Debt Facility Warrants”). The Company was permitted to voluntarily prepay the outstanding Loans at any time, without premium or penalty, upon five business days’ prior written notice to the Lender. The Company was required to prepay outstanding Loans upon the occurrence of (i) any Change of Control or (ii) certain other events as more fully described in the Debt Facility Agreement, but in any event including any capital raise or other transaction pursuant to which the Company received cumulative cash proceeds in excess of $5.0 million in the aggregate (each such event in this prong (ii), a “ Monetization Event The Debt Facility Agreement included other customary representations and warranties, conditions, affirmative and negative covenants, and events of default. Issuance costs incurred through September 30, 2024 in connection with the Debt Facility amounted to $202,656 which included legal fees of $74,532, warrant fair of the warrant issuance in the amount of $53,124 and a transaction fee to the lender in the amount of $75,000 and were initially recorded as a deferred cost on the accompanying balance sheets. The deferred costs were being amortized over the term of the Debt Facility. For the year ended September 30, 2024, $101,329 of the deferred costs were amortized and were included in the financing costs line item in the accompanying statements of operations.

Concentrations

Concentrations	12 Months Ended
	Sep. 30, 2024
Concentrations [Abstract]
Concentrations	NOTE 11 - Concentrations Revenue For the year ended September 30, 2024, one customer accounted for 90% of the Company’s product revenue and three customers accounted for the remaining 10% of product revenue. For the year ended September 30, 2023, one customer accounted for all of the Company’s product and collaborations revenue. Supplier concentration One contract manufacturer produces all of the Company’s Strip/Grid Products and sEEG Products and another supplier was responsible for the development of the Company’s OneRF Ablation system.

Income Taxes

Income Taxes	12 Months Ended
	Sep. 30, 2024
Income Taxes [Abstract]
Income Taxes	NOTE 12 - Income Taxes The effective tax rate for the Company for the years ended September 30, 2024 and 2023 was zero 2024 2023 Income tax benefit at federal statutory rate (21.0 )% (21.0 )% State income tax, net of federal benefit (7.7 ) (7.7 ) Research credits (2.4 ) (1.7 ) Stock-based compensation and other 1.9 0.8 Valuation allowance 29.2 29.6 Effective tax rate — % — % Significant components of the Company’s deferred tax assets and liabilities are summarized in the tables below as of September 30: 2024 2023 Deferred tax assets: Federal and state operating loss carryforwards $ 13,789,594 $ 11,657,158 Acquired intangibles 30,258 28,352 Accruals and other 97,803 63,301 Research and development capitalization 2,650,371 1,780,649 Research and development credit carryforwards 1,609,718 1,314,487 Stock-based compensation 986,952 788,790 Total deferred tax assets 19,164,696 15,632,737 Deferred tax liabilities: Fixed assets and other (136,659 ) (204,829 ) Total deferred tax liabilities (136,659 ) (204,829 ) Valuation allowance (19,028,037 ) (15,427,908 ) Net deferred tax assets $ — $ — As of September 30, 2024 and 2023, the Company had gross deferred tax assets of approximately $19,165,000 and $15,633,000, respectively. Realization of the deferred assets is primarily dependent upon future taxable income, if any, the amount and timing of which are uncertain. The Company has had significant pre-tax losses since its inception. The Company has not yet generated revenues from sales to the level of becoming profitable. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance of approximately $19,028,000 and $15,428,000 as of September 30, 2024 and 2023, respectively. Net deferred tax assets will continue to require a valuation allowance until the Company can demonstrate their realizability through sustained profitability or another source of income. As of September 30, 2024 and 2023, the Company’s federal net operating loss carryforwards were approximately $47,958,000 and $40,571,000, respectively. The Company had federal research credit carryforwards as of September 30, 2024 and 2023 of approximately $1,304,000 and $1,074,000, respectively. The federal net operating loss incurred prior to January 1, 2018 and tax credit carryforwards will begin to expire in 2036 if not utilized. Federal net operating losses incurred after December 31, 2017 will not expire. As of September 30, 2024 and 2023, the Company had state net operating loss carryforwards of approximately $48,030,000 and $40,522,000, respectively. The Company had state research credit carryforwards of approximately $747,000 and $598,000 as of September 30, 2024 and 2023, respectively. The state net operating loss carryforwards will begin to expire in 2031, if not utilized, and the state research credit carryforwards will begin to expire in 2032 if not utilized. Utilization of the net operating loss carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. Generally, in addition to certain entity reorganizations, the limitation applies when one or more “5-percent shareholders” increase their ownership, in the aggregate, by more than 50 percentage points over a 36-month testing period or beginning the day after the most recent ownership change, if shorter. The annual limitation may result in the expiration of net operating losses and credits before utilization. In accordance with ASC 740, Income Taxes (“ASC 740”), specifically related to uncertain tax positions, a Company is required to use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. A reconciliation of the beginning and ending amounts of unrecognized tax positions for the years ended September 30 is as follows: 2024 2023 Unrecognized tax positions, beginning of year $ 231,968 $ — Gross increase, current period tax positions 52,100 231,968 Unrecognized tax positions, end of year $ 284,068 $ 231,968 If recognized, none of the unrecognized tax positions would impact the Company’s income tax benefit or effective tax rate as long as the Company’s net deferred tax assets remain subject to a full valuation allowance. The Company does not expect any significant increases or decreases to the Company’s unrecognized tax positions within the next 12 months. In accordance with this guidance, the Company has adopted a policy under which, if required to be recognized in the future, interest related to the underpayment of income taxes will be classified as a component of interest expense and any related penalties will be classified in operating expenses in the accompanying statements of operations. The Company has tax filing obligations in the following jurisdictions: U.S. federal, Minnesota and California. The income tax returns since 2021 are subject to examination by the federal and state taxing authorities.

Defined Contribution Plan

Defined Contribution Plan	12 Months Ended
	Sep. 30, 2024
Defined Contribution Plan [Abstract]
Defined Contribution Plan	NOTE 13 - Defined Contribution Plan The Company has a 401(k) defined contribution plan (the “401K Plan”) for all employees over age 21. Employees can defer up to 100% of their compensation through payroll withholdings into the 401K Plan subject to federal law limits. The Company may match 100% of deferrals up to 3% of one’s contributions. The Company’s matching contributions to employee deferrals are discretionary. The Company may also make discretionary profit sharing contributions under the 401K Plan in the future, but it has not done so through September 30, 2024. Employee contributions and any employer matching contributions made to satisfy certain non-discrimination tests required by the Internal Revenue Code are 100% vested upon contribution. Discretionary employer matches to employee deferrals vest over a six year period beginning on the second anniversary of an employee’s date of hire. Discretionary profit sharing contributions vest over a five year period beginning on the first anniversary of an employee’s date of hire. The Company did not make any contributions to the 401K Plan during the years ended September 30, 2024 and 2023.

Subsequent Events

Subsequent Events	12 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	NOTE 14 - Subsequent Events On October 25, 2024, we entered into the Zimmer Amended and Restated Distribution Agreement with Zimmer pursuant to which we granted Zimmer the exclusive right and license to distribute our OneRF Ablation System for an upfront payment of $3.0 million, with eligibility for an additional $1.0 million payment from Zimmer upon achievement of certain specified net sales milestones. On November 7, 2024, the Company terminated the Debt Facility Agreement and no amounts were drawn under the Debt Facility Agreement, The Company and paid the standby fee of $125,000 to the Lender.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (12,318,110)	$ (11,859,491)

Insider Trading Arrangements

Insider Trading Arrangements	12 Months Ended
	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Sep. 30, 2024
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying financial statements have been prepared in accordance with accounting standards generally accepted in the United States of America (“U.S. GAAP”).
Reclassifications	Reclassifications Certain amounts presented in the prior year period have been reclassified to conform to current period financial statement presentation. The financing proceeds and issuance costs attributed to the at-the-market offering program and private placement reflected in the statements of cash flows during the comparable prior year period were reclassified into two separate line item categories.
Management’s Use of Estimates	Management’s Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Segment Information	Segment Information Operating segments are components of an enterprise for which separate financial information is available and are evaluated regularly by the Company’s chief operating decision maker in deciding how to allocate resources and assessing performance. The Company’s chief operating decision maker is its Chief Executive Officer. The Company’s Chief Executive Officer views the Company’s operations and manages its business in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions. Accordingly, the Company has a single reporting segment.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an original contractual maturity on date of purchase of less than or equal to three months to be classified and presented as cash equivalents on the balance sheets. Cash equivalents are stated at cost, which approximates fair value. The Company’s cash and cash equivalents may include demand deposit accounts with large financial institutions, institutional money market funds, U.S. Treasury securities, and corporate notes and bonds. The Company monitors the creditworthiness of the financial institutions, institutional money market funds, and corporations in which the Company invests its surplus funds. The Company has experienced no credit losses from its cash and cash equivalent investments.
Short-Term Investments	Short-Term Investments The Company has periodically invested its excess cash in U.S. Treasury securities and highly rated corporate securities. The Company has held these investments to maturity. Securities with original maturity dates of more than three months were reported as held-to-maturity investments and were recorded at amortized cost, which approximated fair value due to the negligible risk of changes in value due to interest rates. There were no short-term investments outstanding as of September 30, 2024 and 2023.
Revenue Recognition	Revenue Recognition The Company entered into a development and distribution agreement which has current and future revenue recognition implications. In addition, the Company has product revenue in connection with its OneRF product offerings (“OneRF Products”) which is not covered by a distribution agreement. See “Note 7 – In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in Accounting Standards Codification (“ASC”) Topic 606 (“ASC 606”). Performance obligations may include license rights, development services, and services associated with regulatory submission and approval processes. Significant management judgment is required to determine the level of effort required under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations are either completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Product Revenue Revenues from product sales are recognized when control of the promised goods or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. When the Company has consigned inventory at a customer, revenue is recognized at the point in time when the customer issues a purchase order to the Company and when control of the promised goods or services is transferred to the Company’s customers. At the inception of each customer contract, performance obligations are identified and the total transaction price is allocated to the performance obligations. Cost of Product Revenue Cost of product revenue consists of the manufacturing and materials costs incurred by the Company’s third-party contract manufacturer in connection with the Company’s strip and grid cortical electrodes (the “Strip/Grid Products”), depth electrodes (“sEEG Products), OneRF Products and outside supplier materials costs in connection with the electrode cable assembly products (“Electrode Cable Assembly Products”). In addition, cost of product revenue includes royalty fees incurred in connection with the Company’s license agreements. Collaborations Revenue As part of the accounting for collaboration arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. The Company allocates the total transaction price to each performance obligation based on the estimated relative standalone selling prices of the promised goods or service underlying each performance obligation. Licenses of intellectual property Milestone payments Royalties
Warrant Liability	Warrant Liability The Company issued warrants in connection with its 2024 Private Placement (See Note 9– Stockholders’ Equity). The Company accounts for these warrants as a liability at fair value when warrant pricing protection provisions are not available to other common stockholders. Additionally, issuance costs associated with the warrant liability are expensed as incurred and reflected as a financing cost in the accompanying statements of operations. The Company adjusts the liability for changes in fair value until the earlier of the exercise or expiration of the warrants for any period when pricing protections remain in place. Any future change in fair value of the warrant liability, when outstanding, is recognized in the statements of operations under the fair value change in warrant liability line item.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (“FASB”) fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows: ● Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date. ● Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. ● Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. As of September 30, 2024 and 2023, the fair values of cash, cash equivalents, accounts receivable, inventory, prepaids and deferred offering costs, accounts payable and accrued expenses and other liabilities approximated their carrying values because of the short-term nature of these assets or liabilities. The fair value of the warrant liability was based on Level 3 inputs as well the Company’s underlying stock price and associated volatility, expected term of the warrants and market interest rates. There were no transfers between fair value hierarchy levels during the years ended September 30, 2024 and 2023. The fair value of financial instruments measured on a recurring basis is as follows: As of September 30, 2024 Description Total Level 1 Level 2 Level 3 Liabilities: Warrant liability $ 2,140,315 $ — $ — $ 2,140,315 Total liabilities at fair value $ 2,140,315 $ — $ — $ 2,140,315 There was not a warrant liability as of September 30, 2023. The following table provides a roll-forward of the warrant liability measured at fair value on a recurring basis using unobservable level 3 inputs for the year ended September 30, 2024. 2024 Warrant liability Balance as of beginning of year $ — Value assigned to warrants in connection with 2024 Private Placement 1,813,223 Change in fair value of warrant liability 327,092 Balance as of end of year $ 2,140,315
Intellectual Property	Intellectual Property The Company has entered into two licensing agreements with major research institutions, which allow for access to certain patented technology and know-how. Payments under those agreements are capitalized and amortized to selling, general and administrative expense over the expected useful life of the acquired technology.
Property and Equipment	Property and Equipment Property and equipment is recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful lives of the assets using the straight-line method. The estimated useful life for equipment and furniture ranges from three to seven years. Tangible assets acquired for research and development activities and that have alternative use are capitalized over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and, when appropriate, changes are made prospectively. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged directly to expense as incurred.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company evaluates its long-lived assets, which consist of licensed intellectual property, property and equipment and right-of-use assets for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset.
Accounts Receivable and Allowances for Credit Losses	Accounts Receivable and Allowances for Credit Losses The Company records a provision for credit losses, when appropriate, based on historical experience, current conditions and reasonable supportable forecasts. In estimating the allowance for credit losses, the Company considers, among other factors, the estimate of credit losses over the remaining expected life of the asset, primarily using historical experience and current economic conditions that could affect the collectability of the balances in the future. Account balances are charged off against the allowance when the Company believes that it is probable that the receivable will not be recovered. Actual write-offs may be in excess of the Company’s estimated allowance. The Company has not incurred any bad debt expense to date and no allowance for credit losses has been recorded during the periods presented.
Inventory	Inventory Inventory is stated at the lower of cost (using the first-in, first-out “FIFO” method) or net realizable value. The Company calculates inventory valuation adjustments for excess and obsolete inventory, when appropriate, based on current inventory levels, movement, expected useful lives, and estimated future demand of the products and spare parts. The Company’s inventory is currently comprised of Strip/Grid Products, sEEG Products, OneRF Products and Electrode Cable Assembly Products component, work-in-process and finished good product. The Strip/Grid Products, sEEG Products and OneRF Products are produced by a third-party contract manufacturer and the Electrode Cable Assembly Products are obtained from outside suppliers. No inventory valuation allowance was required during the periods presented.
Research and Development Costs	Research and Development Costs Research and development costs are charged to expense as incurred. Research and development expenses comprise of costs incurred in performing research and development activities, including compensation and benefits for research and development employees (including stock-based compensation), overhead expenses, cost of laboratory supplies, clinical trial and related clinical manufacturing expenses, costs related to regulatory operations, fees paid to consultants and other outside expenses. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with ASC 730, Research and Development
Advertising Expense	Advertising Expense Advertising expense is charged to selling, general and administrative expenses during the period that it is incurred. Total advertising expense amounted to $108,993 and $173,430 for the years ended September 30, 2024 and 2023, respectively.
Selling, General and Administrative	Selling, General and Administrative Selling, general and administrative expenses consist primarily of personnel-related costs including stock-based compensation for personnel in functions not directly associated with research and development activities. Other significant costs include legal and litigation costs relating to corporate matters, intellectual property costs, professional fees for consultants assisting with financial and administrative matters, and sales and marketing in connection with the commercial sales of the Company’s products.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the provisions of ASC 718, Compensation — Stock Compensation
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized.
Net Loss Per Share	Net Loss Per Share Basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company’s warrants, stock options, and restricted stock units while outstanding are considered common stock equivalents for this purpose. Diluted earnings or loss per share of common stock is computed utilizing the treasury method for the warrants, stock options and restricted stock units. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the years ended September 30, 2024 and 2023. The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the years ended September 30: 2024 2023 Warrants 7,045,875 6,202,426 Stock options 2,814,096 1,708,427 Restricted stock units 1,129,762 393,370
Recent Accounting Pronouncements	Recent Accounting Pronouncements In November 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-07 - Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures In June 2016, the FASB issued Accounting Standards Update 2016-13, Financial Instruments – Credit Losses

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Sep. 30, 2024
Summary of Significant Accounting Policies [Abstract]
Schedule of Fair Value of Financial Instruments	The fair value of financial instruments measured on a recurring basis is as follows: As of September 30, 2024 Description Total Level 1 Level 2 Level 3 Liabilities: Warrant liability $ 2,140,315 $ — $ — $ 2,140,315 Total liabilities at fair value $ 2,140,315 $ — $ — $ 2,140,315
Schedule of Warrant Liability Measured at Fair Value	The following table provides a roll-forward of the warrant liability measured at fair value on a recurring basis using unobservable level 3 inputs for the year ended September 30, 2024. 2024 Warrant liability Balance as of beginning of year $ — Value assigned to warrants in connection with 2024 Private Placement 1,813,223 Change in fair value of warrant liability 327,092 Balance as of end of year $ 2,140,315
Schedule of Computation of Diluted Net Loss Per Share	The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the years ended September 30: 2024 2023 Warrants 7,045,875 6,202,426 Stock options 2,814,096 1,708,427 Restricted stock units 1,129,762 393,370

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Sep. 30, 2024
Commitments and Contingencies [Abstract]
Schedule of Supplemental Cash Flow Information Related to the Operating Lease	Supplemental cash flow information related to the operating lease For the Years Ended 2024 2023 Cash paid for amounts included in the measurement of lease liability: Operating cash flows from operating leases $ 138,917 $ 134,632 Modification of right-of-use asset and associated lease liability: Operating leases $ 199,385 $ 97,536
Schedule of Supplemental Balance Sheet Information Related to the Operating Lease	Supplemental balance sheet information related to the operating lease was as follows: As of 2024 2023 Right-of-use assets $ 254,910 $ 169,059 Lease liability $ 260,160 $ 184,400 Weighted average remaining lease term (years) 3.6 1.4 Weighted average discount rate 7.4 % 7.8 %
Schedule of Maturity of the Lease Liability	Maturity of the lease liability was as follows: Calendar Year As of 2024 $ 35,122 2025 66,097 2026 78,945 2027 81,708 2028 34,815 Total lease payments 296,687 Less imputed interest (36,527 ) Total 260,160 Short term portion in accrued expenses and other liabilities (65,768 ) Long term portion $ 194,392

Supplemental Balance Sheet In_2

Supplemental Balance Sheet Information (Tables)	12 Months Ended
	Sep. 30, 2024
Supplemental Balance Sheet Information [Abstract]
Schedule of Inventory Consisted	Inventory consisted of the following: As of 2024 2023 Component inventory $ 877,065 $ 1,202,778 Work-in-process 192,360 343,597 Finished goods 1,565,728 180,311 Total $ 2,635,153 $ 1,726,686
Schedule of Intangible Assets	Intangible assets roll forward is as follows: Useful Life Net intangibles, September 30, 2022 12-13 years $ 111,892 Less: amortization (22,315 ) Net intangibles, September 30, 2023 89,577 Less: amortization (22,315 ) Net intangibles, September 30, 2024 $ 67,262
Schedule of Property and Equipment	Property and equipment, net held for use by category are presented in the following table: As of 2024 2023 Equipment and furniture $ 976,303 $ 860,737 Total property and equipment 976,303 860,737 Less accumulated depreciation (559,460 ) (334,984 ) Property and equipment, net $ 416,843 $ 525,753

Accrued Expenses and Other Li_2

Accrued Expenses and Other Liabilities (Tables)	12 Months Ended
	Sep. 30, 2024
Accrued Expenses and Other Liabilities [Abstract]
Schedule of Accrued Expenses and Other Liabilities	Accrued expenses and other liabilities consisted of the following As of 2024 2023 Accrued payroll $ 950,260 $ 874,382 Operating lease liability, short term 65,768 129,116 Royalty fees 108,036 104,024 Other 59,950 — Total $ 1,184,014 $ 1,107,522

Zimmer Development Agreement _2

Zimmer Development Agreement and Other Product Revenue (Tables)	12 Months Ended
	Sep. 30, 2024
Zimmer Development Agreement and Other Product Revenue [Abstract]
Schedule of Deferred Revenue	A reconciliation of the closing balance of deferred revenue related to the Zimmer Distribution Agreement and the Zimmer Amendment is as follows as of September 30, 2024 and 2023: Deferred Revenue Balance as of September 30, 2022 $ 1,455,188 Revenue recognized (1,455,188 ) Balance as of September 30, 2023 — Revenue recognized — Balance as of September 30, 2024 $ —

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Sep. 30, 2024
Stock-Based Compensation [Abstract]
Schedule of Stock-Based Compensation Expense	During the years ended September 30, 2024 and 2023, stock-based expense related to the stock options and restricted stock units was included in selling, general and administrative and research and development costs as follows in the accompanying statements of operations: 2024 2023 Selling, general and administrative $ 1,064,819 $ 905,108 Research and development 279,657 200,349 Total stock-based compensation expense $ 1,344,476 $ 1,105,457
Schedule of Stock Option Plan Activity	The following table summarizes the Company’s stock option plan activity for the years ended September 30, 2024 and 2023 as follows: Number of Weighted Weighted- Aggregate Outstanding at September 30, 2022 1,239,915 $ 5.40 8.0 $ 89,295 Granted 469,512 $ 1.55 — — Exercised — $ — — — Forfeited/Cancelled (1,000 ) $ 3.78 — — Outstanding at September 30, 2023 1,708,427 $ 4.34 7.7 $ 20,064 Granted 1,225,669 $ 1.26 — — Exercised — $ — — — Forfeited/Cancelled (120,000 ) $ 1.33 — — Outstanding at September 30, 2024 2,814,096 $ 3.13 7.7 $ 22,685 Vested and expected to vest at September 30, 2024 2,814,096 $ 3.13 7.7 $ 22,685 Vested and exercisable at September 30, 2024 1,409,840 $ 4.79 6.4 $ 22,643
Schedule of Weighted Average Assumptions	The weighted-average assumptions used in the Black-Scholes option-pricing model are as follows for the stock options granted during the years ended September 30: 2024 2023 Expected stock price volatility 111.9 % 57.4 % Expected life of options (years) 6.1 5.8 Expected dividend yield 0 % 0 % Risk free interest rate 4.6 % 3.7 %
Schedule of Summary of Restricted Stock Unit	A summary of restricted stock unit (“RSU”) activity is as follows for the years ended September 30, 2024 and 2023: Number of Shares Non-vested at September 30, 2022 414,430 Granted 310,728 Vested (331,788 ) Non-vested at September 30, 2023 393,370 Granted 1,006,725 Vested (270,333 ) Non-vested at September 30, 2024 1,129,762

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	12 Months Ended
	Sep. 30, 2024
Stockholders’ Equity [Abstract]
Schedule of Warrant Activity and Summary	The following table summarizes warrant activity during the years ended September 30, 2024 and 2023: Warrants Exercise Weighted Weighted Outstanding and exercisable at September 30, 2022 7,103,344 $ 3.00-9.00 $ 5.98 2.68 Issued — $ — $ — — Exercised — $ — $ — — Expired (900,918 ) $ 5.61-9.00 $ 6.38 — Outstanding and exercisable at September 30, 2023 6,202,426 $ 3.00-9.00 $ 5.92 2.00 Issued 2,308,338 $ 0.66-1.19 $ 1.17 3.09 Exercised — $ — $ — — Expired (1,464,889 ) $ 6.00-9.00 $ 8.59 — Outstanding at September 30, 2024 7,045,875 $ 0.66-5.61 $ 3.81 1.98 Outstanding and exercisable at September 30, 2024 7,045,875 $ 0.66-5.61 $ 3.81 1.98
Schedule of Warrants Outstanding	The following table summarizes information about warrants outstanding at September 30, 2024: Exercise Price Number Outstanding Weighted Average Number Exercisable at $ 0.66 100,000 4.84 100,000 $ 1.19 2,208,338 2.84 2,208,338 $ 3.00 350,000 2.84 350,000 $ 5.25 4,166,682 1.29 4,166,682 $ 5.61 220,855 3.75 220,855 Total 7,045,875 7,045,875

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2024
Income Taxes [Abstract]
Schedule of Federal Income Tax Rate to Provision (Benefit) for Income Taxes	A reconciliation of income tax computed at the statutory federal income tax rate to the provision (benefit) for income taxes included in the accompanying statements of operations for the years ended September 30 is as follows: 2024 2023 Income tax benefit at federal statutory rate (21.0 )% (21.0 )% State income tax, net of federal benefit (7.7 ) (7.7 ) Research credits (2.4 ) (1.7 ) Stock-based compensation and other 1.9 0.8 Valuation allowance 29.2 29.6 Effective tax rate — % — %
Schedule of Deferred Tax Assets and Liabilities	Significant components of the Company’s deferred tax assets and liabilities are summarized in the tables below as of September 30: 2024 2023 Deferred tax assets: Federal and state operating loss carryforwards $ 13,789,594 $ 11,657,158 Acquired intangibles 30,258 28,352 Accruals and other 97,803 63,301 Research and development capitalization 2,650,371 1,780,649 Research and development credit carryforwards 1,609,718 1,314,487 Stock-based compensation 986,952 788,790 Total deferred tax assets 19,164,696 15,632,737 Deferred tax liabilities: Fixed assets and other (136,659 ) (204,829 ) Total deferred tax liabilities (136,659 ) (204,829 ) Valuation allowance (19,028,037 ) (15,427,908 ) Net deferred tax assets $ — $ —
Schedule of Unrecognized Tax Positions	A reconciliation of the beginning and ending amounts of unrecognized tax positions for the years ended September 30 is as follows: 2024 2023 Unrecognized tax positions, beginning of year $ 231,968 $ — Gross increase, current period tax positions 52,100 231,968 Unrecognized tax positions, end of year $ 284,068 $ 231,968

Going Concern (Details)

Going Concern (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Going Concern [Abstract]
Accumulated deficit	$ (75,004,413)	$ (62,686,303)

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2024
Summary of Significant Accounting Policies [Abstract]
Advertising expense	$ 108,993	$ 173,430

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of Fair Value of Financial Instruments - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Derivatives, Fair Value [Line Items]
Warrant liability	$ 2,140,315
Total liabilities at fair value	2,140,315
Fair Value, Inputs, Level 1 [Member]
Derivatives, Fair Value [Line Items]
Warrant liability
Total liabilities at fair value
Fair Value, Inputs, Level 2 [Member]
Derivatives, Fair Value [Line Items]
Warrant liability
Total liabilities at fair value
Fair Value, Inputs, Level 3 [Member]
Derivatives, Fair Value [Line Items]
Warrant liability	2,140,315
Total liabilities at fair value	$ 2,140,315

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details) - Schedule of Warrant Liability Measured at Fair Value - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Warrant liability
Balance as of beginning of year
Value assigned to warrants in connection with 2024 Private Placement	1,813,223
Change in fair value of warrant liability	327,092
Balance as of end of year	$ 2,140,315

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details) - Schedule of Computation of Diluted Net Loss Per Share - shares	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Stock Option [Member]
Schedule of Computation of Diluted Net Loss Per Share Abstract [Line Items]
Anti-dilutive net loss	2,814,096	1,708,427
Restricted Stock Units [Member]
Schedule of Computation of Diluted Net Loss Per Share Abstract [Line Items]
Anti-dilutive net loss	1,129,762	393,370
Warrant [Member]
Schedule of Computation of Diluted Net Loss Per Share Abstract [Line Items]
Anti-dilutive net loss	7,045,875	6,202,426

Commitments and Contingencies_2

Commitments and Contingencies (Details)			12 Months Ended
	Jan. 01, 2023 USD ($)	Jul. 01, 2021 USD ($) m²	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2020 USD ($)	Nov. 04, 2022
Commitments and Contingencies [Line Items]
Annual royalty payment			$ 150,000	$ 150,000
Number of days to remedy default			90 days
Lease space (in Square Meters) | m²		1,162
Initial rent amount		$ 4,241
Additional extended term								2 years
Operating lease			Accounts payable	Accounts payable
Mayo Agreement [Member]
Commitments and Contingencies [Line Items]
Annual royalty payment			$ 6,861	$ 7,486
WARF License Agreement [Member]
Commitments and Contingencies [Line Items]
Annual royalty payment					$ 150,000	$ 100,000	$ 50,000
Written license notice period			30 days
Los Gatos Lease [Member]
Commitments and Contingencies [Line Items]
Operating Lease, Lease Income, Lease Payments			$ 173,090
Los Gatos Lease [Member] | Mayo Agreement [Member]
Commitments and Contingencies [Line Items]
Operating Lease, Lease Income, Lease Payments				$ 171,633
Minimum [Member]
Commitments and Contingencies [Line Items]
Base rent value	$ 4,453		6,410
Maximum [Member]
Commitments and Contingencies [Line Items]
Base rent value	$ 4,632		$ 7,107

Commitments and Contingencies_3

Commitments and Contingencies (Details) - Schedule of Supplemental Cash Flow Information Related to the Operating Lease - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Schedule of Supplemental Cash Flow Information Related to the Operating Leases [Abstract]
Operating cash flows from operating leases	$ 138,917	$ 134,632
Operating leases	$ 199,385	$ 97,536

Commitments and Contingencies_4

Commitments and Contingencies (Details) - Schedule of Supplemental Balance Sheet Information Related to the Operating Lease - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Schedule of Supplemental Balance Sheet Information Related to the Operating Lease [Abstract]
Right-of-use assets	$ 254,910	$ 169,059
Lease liability	$ 260,160	$ 184,400
Weighted average remaining lease term (years)	3 years 7 months 6 days	1 year 4 months 24 days
Weighted average discount rate	7.40%	7.80%

Commitments and Contingencies_5

Commitments and Contingencies (Details) - Schedule of Maturity of the Lease Liability - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Schedule of Maturity of the Lease Liabilities [Abstract]
2024	$ 35,122
2025	66,097
2026	78,945
2027	81,708
2028	34,815
Total lease payments	296,687
Less imputed interest	(36,527)
Total	260,160	$ 184,400
Short term portion in accrued expenses and other liabilities	(65,768)	(129,116)
Long term portion	$ 194,392	$ 55,284

Supplemental Balance Sheet In_3

Supplemental Balance Sheet Information (Details) - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Supplemental Balance Sheet Information [Line Items]
Finished goods on consignment	$ 102,318	$ 0
Depreciation expense	224,476	176,951
Equipment net book value		39,643
Net proceeds		$ 7,500
License Agreement Year 2025 [Member]
Supplemental Balance Sheet Information [Line Items]
Amortization expense	22,000
License Agreement Year 2026 [Member]
Supplemental Balance Sheet Information [Line Items]
Amortization expense	22,000
License Agreement Year 2027 [Member]
Supplemental Balance Sheet Information [Line Items]
Amortization expense	$ 22,000

Supplemental Balance Sheet In_4

Supplemental Balance Sheet Information (Details) - Schedule of Inventory Consisted - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Schedule of Inventory Consisted [Abstract]
Component inventory	$ 877,065	$ 1,202,778
Work-in-process	192,360	343,597
Finished goods	1,565,728	180,311
Total	$ 2,635,153	$ 1,726,686

Supplemental Balance Sheet In_5

Supplemental Balance Sheet Information (Details) - Schedule of Intangible Assets - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Schedule of Intangible Assets [Line Items]
Net Intangibles, beginning	$ 89,577	$ 111,892
Less: amortization	(22,315)	(22,315)
Net Intangibles, ending	$ 67,262	$ 89,577
Minimum [Member]
Schedule of Intangible Assets [Line Items]
Net Intangibles useful life		12 years
Maximum [Member]
Schedule of Intangible Assets [Line Items]
Net Intangibles useful life		13 years

Supplemental Balance Sheet In_6

Supplemental Balance Sheet Information (Details) - Schedule of Property and Equipment - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Schedule of Property and Equipment [Abstract]
Equipment and furniture	$ 976,303	$ 860,737
Total property and equipment	976,303	860,737
Less accumulated depreciation	(559,460)	(334,984)
Property and equipment, net	$ 416,843	$ 525,753

Accrued Expenses and Other Li_3

Accrued Expenses and Other Liabilities (Details) - Schedule of Accrued Expenses and Other Liabilities - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Schedule of Accrued Expenses and Other Liabilities [Abstract]
Accrued payroll	$ 950,260	$ 874,382
Operating lease liability, short term	65,768	129,116
Royalty fees	108,036	104,024
Other	59,950
Total	$ 1,184,014	$ 1,107,522

Zimmer Development Agreement _3

Zimmer Development Agreement and Other Product Revenue (Details) - USD ($)		12 Months Ended
	Aug. 02, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2020
Zimmer Development Agreement [Line Items]
Fee payment				$ 2,000,000
Payment to the company	$ 3,500,000
Fair value of warrant		$ 100,000
Risk-free interest rate		4.60%	3.70%
Expected volatility percentage		111.90%	57.40%
Expected term		6 years 1 month 6 days	5 years 9 months 18 days
Expected dividend yield		0%	0%
Aggregate transaction price		$ 5,400,000
Collaborations revenue amount			$ 1,455,188
Product revenue		3,453,003	$ 1,952,441
One RF Products [Member]
Zimmer Development Agreement [Line Items]
Product revenue		$ 340,185
2022 Zimmer Warrant [Member]
Zimmer Development Agreement [Line Items]
Aggregate shares (in Shares)		350,000
Warrant exercise price (in Dollars per share)		$ 3
Fair value of warrant		$ 100,000
Risk-free interest rate		2.90%
Expected volatility percentage		53.50%
Expected term		5 years
Expected dividend yield		0%
Development Agreement [Member]
Zimmer Development Agreement [Line Items]
Maintenance Fee	1,500,000
Milestone payments paid	$ 2,000,000
Zimmer Distribution Agreement [Member]
Zimmer Development Agreement [Line Items]
Payments for Other Fees		$ 2,000,000
Zimmer Amendment [Member]
Zimmer Development Agreement [Line Items]
Payments for Other Fees		$ 3,500,000

Zimmer Development Agreement _4

Zimmer Development Agreement and Other Product Revenue (Details) - Schedule of Deferred Revenue - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Schedule of Deferred Revenue [Abstract]
Balance		$ 1,455,188
Revenue recognized		(1,455,188)
Balance

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($)					12 Months Ended
	Jan. 01, 2024	Nov. 09, 2023	Jan. 01, 2023	Oct. 01, 2021	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022	Oct. 04, 2021
Stock-Based Compensation [Line Items]
Granted shares					1,225,669	469,512
Total share based expenses (in Dollars)					$ 1,344,476	$ 1,105,457
Aggregate intrinsic per share (in Dollars per share)					$ 0.99	$ 0.89
Stock options outstanding					2,814,096	1,708,427	1,239,915
Stock options exercised
Stock Options [Member]
Stock-Based Compensation [Line Items]
Granted shares					1,225,669	459,512
Grant date fair value of options granted (in Dollars per share)					$ 1.08	$ 0.88
Stock options expiration period					10 years
Total share based expenses (in Dollars)					$ 808,057	$ 632,315
Stock options outstanding					2,780,581	1,682,912
Stock Options [Member]
Stock-Based Compensation [Line Items]
Stock options vested					289,072	337,753
Stock options forfeited					120,000	1,000
Stock options exercised
Restricted Stock Units (RSUs) [Member]
Stock-Based Compensation [Line Items]
Share-based compensation granted, vesting period					4 years
Total share based expenses (in Dollars)					$ 536,419	$ 473,142
Restricted stock units granted					1,006,725	310,728
Restricted stock units, grant date fair value (in Dollars per share)					$ 1.03	$ 1.6
Restricted stock units vest					270,333	331,788
Others Vesting [Member] | Restricted Stock Units (RSUs) [Member]
Stock-Based Compensation [Line Items]
Other restricted stock units vesting, percentage					50%
Maximum [Member] | Stock Options [Member]
Stock-Based Compensation [Line Items]
Share-based compensation granted, vesting period					4 years
Maximum [Member] | Restricted Stock Units (RSUs) [Member]
Stock-Based Compensation [Line Items]
Share-based compensation granted, vesting period						3 years
Minimum [Member] | Restricted Stock Units (RSUs) [Member]
Stock-Based Compensation [Line Items]
Share-based compensation granted, vesting period						1 year
2016 Equity Incentive Plan [Member]
Stock-Based Compensation [Line Items]
Number of shares issuance
2017 Equity Incentive Plan and 2021 Inducement Plan [Member]
Stock-Based Compensation [Line Items]
Number of shares grants								420,350
Shares available for future issuance					297,461
Unrecognized stock-based compensation (in Dollars)					$ 2,373,628
Share-based compensation expected to be recognized, term					2 years 3 months 18 days
Amended Inducement Plan [Member]
Stock-Based Compensation [Line Items]
Number of shares issuance		150,000
Number of shares authorized		570,350
2017 Equity Incentive Plan [Member]
Stock-Based Compensation [Line Items]
Shares outstanding percentage					13%
Option plan shares	1,051,556		129,479
Others Vesting [Member] | Restricted Stock Units (RSUs) [Member]
Stock-Based Compensation [Line Items]
Share-based compensation granted, vesting period					24 months

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details) - Schedule of Stock-Based Compensation Expense - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Schedule of Stock-Based Compensation Expense [Line Items]
Total stock-based compensation expense	$ 1,344,476	$ 1,105,457
Selling, general and administrative [Member]
Schedule of Stock-Based Compensation Expense [Line Items]
Total stock-based compensation expense	1,064,819	905,108
Research and development [Member]
Schedule of Stock-Based Compensation Expense [Line Items]
Total stock-based compensation expense	$ 279,657	$ 200,349

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details) - Schedule of Stock Option Plan Activity - USD ($)		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2024	Sep. 30, 2023
Schedule of Stock Option Plan Activity [Abstract]
Number of Options, Granted		1,225,669	469,512
Weighted Average Exercise Price, Granted		$ 1.26	$ 1.55
Exercised
Exercised
Number of Options, Forfeited/Cancelled		(120,000)	(1,000)
Weighted Average Exercise Price, Forfeited/Cancelled		$ 1.33	$ 3.78
Number of Options, Outstanding, ending	1,239,915	2,814,096	1,708,427
Weighted Average Exercise Price, Outstanding, ending	$ 5.4	$ 3.13	$ 4.34
Weighted- Average Remaining Contractual Term (years), Outstanding, ending	8 years	7 years 8 months 12 days	7 years 8 months 12 days
Aggregate Intrinsic Value, Outstanding, ending	$ 89,295	$ 22,685	$ 20,064
Number of Options, Vested and expected to vest at September 30, 2024		2,814,096
Weighted Average Exercise Price, Vested and expected to vest at September 30, 2024		$ 3.13
Weighted- Average Remaining Contractual Term (years), Vested and expected to vest at September 30, 2024		7 years 8 months 12 days
Aggregate Intrinsic Value, Vested and expected to vest at September 30, 2024		$ 22,685
Number of Options, Vested and exercisable at September 30, 2024		1,409,840
Weighted Average Exercise Price, Vested and exercisable at September 30, 2024		$ 4.79
Weighted- Average Remaining Contractual Term (years), Vested and exercisable at September 30, 2024		6 years 4 months 24 days
Aggregate Intrinsic Value, Vested and exercisable at September 30, 2024		$ 22,643

Stock-Based Compensation (Det_4

Stock-Based Compensation (Details) - Schedule of Weighted Average Assumptions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Schedule of Weighted Average Assumptions [Abstract]
Expected stock price volatility	111.90%	57.40%
Expected life of options (years)	6 years 1 month 6 days	5 years 9 months 18 days
Expected dividend yield	0%	0%
Risk free interest rate	4.60%	3.70%

Stock-Based Compensation (Det_5

Stock-Based Compensation (Details) - Schedule of Summary of Restricted Stock Unit - Restricted Stock Units (RSUs) [Member] - shares	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Non-vested at beginning	393,370	414,430
Granted	1,006,725	310,728
Vested	(270,333)	(331,788)
Non-vested at ending	1,129,762	393,370

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - USD ($)						1 Months Ended	12 Months Ended
	Aug. 16, 2024	Aug. 02, 2024	Aug. 01, 2024	Jul. 24, 2023	Dec. 21, 2022	Jul. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Jan. 05, 2024	Dec. 01, 2023
Stockholders’ Equity [Line Items]
Issuance and sale of shares (in Shares)			2,944,446	5,250,000
Public price per share (in Dollars per share)			$ 0.001
Issuance of common stock in connection with public offering (in Shares)			2,208,333
Shares Issued, Price Per Share (in Dollars per share)			$ 0.9
Exercise price per share (in Dollars per share)			$ 0.75				$ 1.19
Gross proceeds			$ 2,650,000
Issuance costs in connection with at-the-market offering program							$ 236,597	$ 234,725
Risk-free interest rate							4.60%	3.70%
Expected volatility rate							111.90%	57.40%
Expected life							6 years 1 month 6 days	5 years 9 months 18 days
Expected dividend yield							0%	0%
Proceeds from issuance of warrants in connection with private placement							$ 1,813,223
Fair value change in warrant liability							$ 327,092
Maximum aggregate common stock offering price				$ 2,600,000	$ 14,500,000				$ 9,300,000	$ 4,800,000
Percentage of gross proceeds					3%
Amount of common stock of sales agreement	$ 3,000,000
Share issued (in Shares)							3,748,913	1,439,677
Aggregate offering price							$ 5,033,906	$ 2,552,656
Common stock issued (in Shares)							30,816,499	23,928,945
Common stock, par value (in Dollars per share)							$ 0.001	$ 0.001
Purchased additional shares (in Shares)				787,500
Net proceeds						$ 5,200,000
At The Market Offering [Member]
Stockholders’ Equity [Line Items]
Issuance costs in connection with at-the-market offering program							$ 277,903	$ 234,725
Maximum aggregate common stock offering price							7,586,562
Deferred cost							41,305
At The Market Offering [Member] | ATM [Member]
Stockholders’ Equity [Line Items]
Issuance costs in connection with at-the-market offering program							$ 512,628
Common Stock [Member]
Stockholders’ Equity [Line Items]
Issuance of common stock in connection with public offering (in Shares)								6,037,500
Common stock, par value (in Dollars per share)				$ 0.001
Common Stock [Member] | At The Market Offering [Member]
Stockholders’ Equity [Line Items]
Common stock issued (in Shares)							5,188,590
August 2024 Private Placement [Member]
Stockholders’ Equity [Line Items]
Issuance costs in connection with at-the-market offering program			$ 200,000
Risk-free interest rate		3.63%					3.53%
Expected volatility rate		116.10%					115.70%
Expected life		3 years					2 years 10 months 2 days
Expected dividend yield		0%
July 2023 Public Offering [Member]
Stockholders’ Equity [Line Items]
Public price per share (in Dollars per share)				$ 1
Over-Allotment Option [Member] | Common Stock [Member]
Stockholders’ Equity [Line Items]
Issuance of common stock in connection with public offering (in Shares)				6,037,500

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - Schedule of Warrant Activity and Summary - Warrant [Member] - $ / shares		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2024	Sep. 30, 2023
Schedule of Warrant Activity and Summary [Line Items]
Warrants, Outstanding and exercisable, Ending (in Shares)	7,103,344	7,045,875	6,202,426
Weighted Average Exercise Price, Outstanding and exercisable, Ending	$ 5.98	$ 3.81	$ 5.92
Weighted Average Term (Years), Outstanding and exercisable, Ending	2 years 8 months 4 days	1 year 11 months 23 days	2 years
Warrants, Issued (in Shares)		2,308,338
Exercise Price Per Warrant, Issued
Weighted Average Exercise Price, Issued		$ 1.17
Weighted Average Term (Years), Issued		3 years 1 month 2 days
Warrants, Exercised (in Shares)
Exercise Price Per Warrant, Exercised
Weighted Average Exercise Price, Exercised
Weighted Average Term (Years), Exercised
Warrants, Expired (in Shares)		(1,464,889)	(900,918)
Weighted Average Exercise Price, Expired		$ 8.59	$ 6.38
Weighted Average Term (years), Expired
Minimum [Member]
Schedule of Warrant Activity and Summary [Line Items]
Exercise Price Per Warrant, Outstanding and exercisable, Ending	$ 3	$ 0.66	$ 3
Exercise Price Per Warrant, Issued		0.66
Exercise Price Per Warrant, Expired		6	5.61
Maximum [Member]
Schedule of Warrant Activity and Summary [Line Items]
Exercise Price Per Warrant, Outstanding and exercisable, Ending	$ 9	5.61	9
Exercise Price Per Warrant, Issued		1.19
Exercise Price Per Warrant, Expired		$ 9	$ 9

Stockholders_ Equity (Details_2

Stockholders’ Equity (Details) - Schedule of Warrants Outstanding - Warrant [Member]	12 Months Ended
	Sep. 30, 2024 $ / shares shares
3.00 [Member]
Schedule of Warrants Outstanding [Line Items]
Exercise Price, Total (in Dollars per share) | $ / shares	$ 0.66
Number Outstanding, Total	100,000
Weighted Average Remaining Contractual life (Years), Total	4 years 10 months 2 days
Number Exercisable , Total	100,000
5.25 [Member]
Schedule of Warrants Outstanding [Line Items]
Exercise Price, Total (in Dollars per share) | $ / shares	$ 1.19
Number Outstanding, Total	2,208,338
Weighted Average Remaining Contractual life (Years), Total	2 years 10 months 2 days
Number Exercisable , Total	2,208,338
5.61 [Member]
Schedule of Warrants Outstanding [Line Items]
Exercise Price, Total (in Dollars per share) | $ / shares	$ 3
Number Outstanding, Total	350,000
Weighted Average Remaining Contractual life (Years), Total	2 years 10 months 2 days
Number Exercisable , Total	350,000
6.00 [Member]
Schedule of Warrants Outstanding [Line Items]
Exercise Price, Total (in Dollars per share) | $ / shares	$ 5.25
Number Outstanding, Total	4,166,682
Weighted Average Remaining Contractual life (Years), Total	1 year 3 months 14 days
Number Exercisable , Total	4,166,682
8.25 [Member]
Schedule of Warrants Outstanding [Line Items]
Exercise Price, Total (in Dollars per share) | $ / shares	$ 5.61
Number Outstanding, Total	220,855
Weighted Average Remaining Contractual life (Years), Total	3 years 9 months
Number Exercisable , Total	220,855
9.00 [Member]
Schedule of Warrants Outstanding [Line Items]
Number Outstanding, Total	7,045,875
Number Exercisable , Total	7,045,875

Debt Financing (Details)

Debt Financing (Details) - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Aug. 02, 2024
Debt Financing [Line Items]
Warrant exercisable term	5 years
Warrants exercisable into common stock (in Shares)	50,000
Exercise price of warrants issued (in Dollars per share)	$ 0.66
Loans borrowed	$ 500,000
Cash proceeds	5,000,000
Issuance costs	202,656
Legal fees	74,532
Non-cash warrants issued in connection with debt facility	53,124
Transaction fee amount	75,000
Deferred costs	$ 101,329
Debt Facility Financing [Member]
Debt Financing [Line Items]
Aggregate principal amount			$ 3,000,000
Outstanding principal amount	10%
Warrant exercisable term	5 years
Warrants exercisable into common stock (in Shares)	100,000

Concentrations (Details)

Concentrations (Details) - Customer Concentration Risk [Member] - Revenue Benchmark [Member]	12 Months Ended
	Sep. 30, 2024
One Customer [Member]
Concentrations [Line Items]
Number of customers	one
Concentration risk, percentage	90%
Three Customers [Member]
Concentrations [Line Items]
Number of customers	three
Concentration risk, percentage	10%

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 30, 2024	Dec. 30, 2023
Income Taxes [Line Items]
Effective tax rate
Gross deferred tax assets	$ 19,165,000	$ 15,633,000
Net deferred tax assets	19,028,000	15,428,000
Operating loss carryforwards	$ 47,958,000	40,571,000
Research credit carryforward			$ 1,609,718	$ 1,314,487
Unrecognized tax position	12 months
Minimum [Member] | Shareholders [Member]
Income Taxes [Line Items]
Ownership percentage	5%
Maximum [Member] | Shareholders [Member]
Income Taxes [Line Items]
Ownership percentage	50%
Federal Research [Member]
Income Taxes [Line Items]
Research credit carryforward	$ 1,304,000	1,074,000
State [Member]
Income Taxes [Line Items]
Operating loss carryforwards	48,030,000	40,522,000
Research credit carryforward	$ 747,000	$ 598,000

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of Federal Income Tax Rate to Provision (Benefit) for Income Taxes	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Schedule of Federal Income Tax Rate to Provision (Benefit) for Income Taxes [Abstract]
Income tax benefit at federal statutory rate	(21.00%)	(21.00%)
State income tax, net of federal benefit	(7.70%)	(7.70%)
Research credits	(2.40%)	(1.70%)
Stock-based compensation and other	1.90%	0.80%
Valuation allowance	29.20%	29.60%
Effective tax rate

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of Deferred Tax Assets and Liabilities - USD ($)	Dec. 30, 2024	Dec. 30, 2023
Deferred tax assets:
Federal and state operating loss carryforwards	$ 13,789,594	$ 11,657,158
Acquired intangibles	30,258	28,352
Accruals and other	97,803	63,301
Research and development capitalization	2,650,371	1,780,649
Research and development credit carryforwards	1,609,718	1,314,487
Stock-based compensation	986,952	788,790
Total deferred tax assets	19,164,696	15,632,737
Deferred tax liabilities:
Fixed assets and other	(136,659)	(204,829)
Total deferred tax liabilities	(136,659)	(204,829)
Valuation allowance	(19,028,037)	(15,427,908)
Net deferred tax assets

Income Taxes (Details) - Sche_3

Income Taxes (Details) - Schedule of Unrecognized Tax Positions - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Schedule of Unrecognized Tax Positions [Abstract]
Unrecognized tax positions, beginning of year	$ 231,968
Gross increase, current period tax positions	52,100	231,968
Unrecognized tax positions, end of year	$ 284,068	$ 231,968

Defined Contribution Plan (Deta

Defined Contribution Plan (Details)	12 Months Ended
	Sep. 30, 2024
Defined Contribution Plan [Abstract]
Deferral compensation percentage	100%
Contribution match percentage	100%
Deferrals percentage of contribution	3%
Internal revenue code vested percentage	100%

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - USD ($)	Nov. 07, 2024	Oct. 25, 2024
Subsequent Events [Line Items]
Upfront payment		$ 3,000,000
Additional payment		$ 1,000,000
New Debt Facility Agreement [Member]
Subsequent Events [Line Items]
Facility fee	$ 125,000